Goudsmit J - Search Results

1

Genomic diversity and antigenic variation of HIV-1: links between pathogenesis, epidemiology and vaccine development.

Goudsmit J, Back NK, Nara PL. Goudsmit J, et al. FASEB J. 1991 Jul;5(10):2427-36. doi: 10.1096/fasebj.5.10.2065891. FASEB J. 1991. PMID: 2065891 Review.

2

Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection.

Goudsmit J, Kuiken CL, Nara PL. Goudsmit J, et al. AIDS. 1989;3 Suppl 1:S119-23. doi: 10.1097/00002030-198901001-00017. AIDS. 1989. PMID: 2482053 Review. No abstract available.

3

Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.

Wolfs TF, Nara PL, Goudsmit J. Wolfs TF, et al. Among authors: goudsmit j. Chem Immunol. 1993;56:1-33. Chem Immunol. 1993. PMID: 8383980 Review. No abstract available.

4

Neutralization of HIV-1: a paradox of humoral proportions.

Nara PL, Garrity RR, Goudsmit J. Nara PL, et al. Among authors: goudsmit j. FASEB J. 1991 Jul;5(10):2437-55. doi: 10.1096/fasebj.5.10.1712328. FASEB J. 1991. PMID: 1712328 Review.

5

Antibody reactivity to deletion mutants of the HIV-1 SF2 envelope.

Back NK, Haigwood NL, de Wolf F, de Jongh BM, Goudsmit J. Back NK, et al. Among authors: goudsmit j. Intervirology. 1991;32(3):160-72. doi: 10.1159/000150196. Intervirology. 1991. PMID: 2040587

6

Antibody recognition of amino acid divergence within an HIV-1 neutralization epitope.

Goudsmit J, Zwart G, Bakker M, Smit L, Back N, Epstein L, Kuiken C, d'Amaro J, de Wolf F. Goudsmit J, et al. Res Virol. 1989 Sep-Oct;140(5):419-36. doi: 10.1016/s0923-2516(89)80120-7. Res Virol. 1989. PMID: 2479966

7

Development and evaluation of an HIV-1 transfection-neutralization assay.

Back NK, Smit L, Hogervorst E, van Wijk AC, Goudsmit J, Tersmette M. Back NK, et al. Among authors: goudsmit j. J Acquir Immune Defic Syndr (1988). 1994 Jun;7(6):531-8. J Acquir Immune Defic Syndr (1988). 1994. PMID: 7513760

8

Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.

Hogervorst E, de Jong J, van Wijk A, Bakker M, Valk M, Nara P, Goudsmit J. Hogervorst E, et al. Among authors: goudsmit j. J Virol. 1995 Oct;69(10):6342-51. doi: 10.1128/JVI.69.10.6342-6351.1995. J Virol. 1995. PMID: 7666535 Free PMC article.

9

The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?

Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R, Koot M, Schuitemaker H, Goudsmit J. Jurriaans S, et al. Among authors: goudsmit j. Virology. 1994 Oct;204(1):223-33. doi: 10.1006/viro.1994.1526. Virology. 1994. PMID: 7916514

10

Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.

Zwart G, Back NK, Ramautarsing C, Valk M, van der Hoek L, Goudsmit J. Zwart G, et al. Among authors: goudsmit j. AIDS Res Hum Retroviruses. 1994 Mar;10(3):245-51. doi: 10.1089/aid.1994.10.245. AIDS Res Hum Retroviruses. 1994. PMID: 8018385

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

582 results

Search Page

Filters